Zobrazeno 1 - 10
of 315
pro vyhledávání: '"Tarek Hassanein"'
Autor:
Man-Fung Yuen, Scott Fung, Xiaoli Ma, Tuan T. Nguyen, Tarek Hassanein, Hie-Won Hann, Magdy Elkhashab, Ronald G. Nahass, James S. Park, Ira M. Jacobson, Walid S. Ayoub, Steven-Huy Han, Edward J. Gane, Katie Zomorodi, Ran Yan, Julie Ma, Steven J. Knox, Luisa M. Stamm, Maurizio Bonacini, Frank Weilert, Alnoor Ramji, Michael Bennett, Natarajan Ravendhran, Sing Chan, Douglas T. Dieterich, Paul Yien Kwo, Eugene R. Schiff, Ho S. Bae, Jacob Lalezari, Kosh Agarwal, Mark S. Sulkowski
Publikováno v:
JHEP Reports, Vol 6, Iss 4, Pp 100999- (2024)
Background & Aims: The investigational first-generation core inhibitor vebicorvir (VBR) demonstrated safety and antiviral activity over 24 weeks in two phase IIa studies in patients with chronic HBV infection. In this long-term extension study, patie
Externí odkaz:
https://doaj.org/article/79c1f480374a43d2b19433829b3f31b0
Publikováno v:
BMC Public Health, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background It is well documented that Egypt has the highest prevalence of hepatitis C virus (HCV) infection in the world. The recent development of highly effective direct acting antiviral drugs (DAAs), has opened the possibility of treating
Externí odkaz:
https://doaj.org/article/0ca95774caee4e60b63260f3cdbc21dc
Autor:
Eric Lawitz, Edward Gane, Eric Cohen, John Vierling, Kosh Agarwal, Tarek Hassanein, Parvez S. Mantry, Paul J. Pockros, Michael Bennett, Nyingi Kemmer, Giuseppe Morelli, Jiuhong Zha, Deli Wang, Nancy S. Shulman, Daniel E. Cohen, K. Rajender Reddy
Publikováno v:
Kidney International Reports, Vol 4, Iss 2, Pp 257-266 (2019)
Introduction: Hepatitis C virus (HCV) infection is common in patients with end-stage renal disease. We investigated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) in 2 phase 3, open-
Externí odkaz:
https://doaj.org/article/4057d33cf90442e09159e38451382b6a
Autor:
Rafael Bañares, Luis Ibáñez-Samaniego, Josep María Torner, Marco Pavesi, Carmen Olmedo, María Vega Catalina, Agustín Albillos, Fin Stolze Larsen, Frederik Nevens, Tarek Hassanein, Harmuth Schmidt, Uwe Heeman, Rajiv Jalan, Richard Moreau, Vicente Arroyo
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 12 (2019)
Background: Acute-on-chronic liver failure (ACLF) is a common complication of cirrhosis characterized by single or multiple organ failures and high short-term mortality. Treatment of ACLF consists of standard medical care (SMC) and organ(s) support.
Externí odkaz:
https://doaj.org/article/ee5401b8fc274f698f9ddcd37c962db2
Autor:
Donald M. Jensen, Tarik Asselah, Douglas Dieterich, Graham R. Foster, Mark S. Sulkowski, Stefan Zeuzem, Parvez Mantry, Eric M. Yoshida, Christophe Moreno, Denis Ouzan, Mark Wright, Luis E. Morano, Robert Buynak, Marc Bourlière, Tarek Hassanein, Shuhei Nishiguchi, Jia-Horng Kao, Masao Omata, Seung W. Paik, David K. Wong, Edward Tam, Kelly Kaita, S. Victor Feinman, Jerry O. Stern, Joseph Scherer, Anne-Marie Quinson, Florian Voss, John-Paul Gallivan, Wulf O. Böcher, Peter Ferenci
Publikováno v:
Annals of Hepatology, Vol 15, Iss 3, Pp 333-349 (2016)
Introduction & aim. Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1 and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naï
Externí odkaz:
https://doaj.org/article/dda945401c9c4406bf45486119425e6e
Autor:
Maiko Sakamoto, Robin C. Hilsabeck, Meghan Hammel, Fatma Barakat, Tarek Hassanein, William Perry
Publikováno v:
Neuropsychological Trends, Vol 17, Pp 67-83 (2015)
t is well established that patients with end stage liver disease (ESLD) experience cognitive and mood problems; however, little is known about changes in cognitive and emotional functioning following liver transplantation, especially over the past de
Externí odkaz:
https://doaj.org/article/5260086020484e8897ceac848d4bbfad
Autor:
Graham R Foster, Carmine Coppola, Moutaz Derbala, Peter Ferenci, Alessandra Orlandini, K Rajender Reddy, Ludovico Tallarico, Mitchell L Shiffman, Silke Ahlers, Georgios Bakalos, Tarek Hassanein, GUARD-C Study Group
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0151703 (2016)
Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline pre
Externí odkaz:
https://doaj.org/article/3320dc0aafb54ec984e74a88f0ea58b4
Autor:
Tarek Hassanein, Craig J. McClain, Vatsalya Vatsalya, Lance L. Stein, Steven L. Flamm, Paul Martin, Matthew C. Cave, Mack Mitchell, Bruce Barton, Laura Nagy, Gyongyi Szabo, Arthur McCullough, Srinivasin Dasarathy, Jaymin Shah, Christina Blevins, Deborah Scott, William Krebs, James E. Brown, WeiQi Lin
Publikováno v:
American Journal of Gastroenterology.
Autor:
Man-Fung Yuen, Kosh Agarwal, Xiaoli Ma, Tuan T. Nguyen, Eugene R. Schiff, Hie-Won L. Hann, Douglas T. Dieterich, Ronald G. Nahass, James S. Park, Sing Chan, Steven-Huy B. Han, Edward J. Gane, Michael Bennett, Katia Alves, Marc Evanchik, Ran Yan, Qi Huang, Uri Lopatin, Richard Colonno, Julie Ma, Steven J. Knox, Luisa M. Stamm, Maurizio Bonacini, Ira M. Jacobson, Walid S. Ayoub, Frank Weilert, Natarajan Ravendhran, Alnoor Ramji, Paul Yien Kwo, Magdy Elkhashab, Tarek Hassanein, Ho S. Bae, Jacob P. Lalezari, Scott K. Fung, Mark S. Sulkowski
Publikováno v:
Journal of Hepatology. 77:642-652
HBV nucleos(t)ide reverse transcriptase inhibitors (NrtIs) do not completely suppress HBV replication. Previous reports indicate persistent viremia during NrtI treatment despite HBV DNA being undetectable. HBV core inhibitors may enhance viral suppre
Autor:
Frank L. Meyskens, Luz M. Rodriguez, Rachel Gonzalez, Ellen Richmond, Wen-Pin Chen, Lorene Kong, Thomas D. Boyer, Tarek Hassanein, Ke-Qin Hu, John C. Hoefs, Neville Pimstone, Teodoro Bottiglieri, Kathryn Osann, Timothy R. Morgan
In animal models of hepatocellular carcinoma (HCC), deficiency of S-adenosylmethionine (SAMe) increased the risk of HCC whereas administration of SAMe reduced HCC. The aim of this trial was to determine whether oral SAMe administration to patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e827d08a120296e6831a2b04d40ed156
https://doi.org/10.1158/1940-6207.c.6545115.v1
https://doi.org/10.1158/1940-6207.c.6545115.v1